Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT06596941
Active, not recruiting Observational

Ultrasound Assessment of Isolated Distal Deep Vein Thrombosis

NCT06596941 · tracked via the Priya Life Science China tracker
Sponsor
Ruijin Hospital
Phase
Observational
Started
2024-01-01
Last updated
2024-09-19

Condition(s) studied

IddvtPulmonary Embolism (PE)

Study summary

Retrospective assessment of ultrasound and clinical characteristics of patients with IDDVT, development of a pulmonary embolism risk prediction model for thrombus, and provision of appropriate diagnostic and therapeutic recommendations.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: Diagnosis of new-onset IDDVT confirmed by lower limb vascular ultrasound; presence/absence of pulmonary embolism clarified by pulmonary artery CTA; ultrasound and pulmonary artery CTA results spanning no more than 5 days. Exclusion Criteria: Anticoagulation therapy in the last month; pregnancy or puerperium; recurrent DVT or PE.

Primary outcome measure(s)

  • IDDVT with PE — At the initial visit
    IDDVT patients with concomitant PE

Trial sites (1)

FacilityCityRegionStatus
Ruijin Hospital,Shanghai Jiao Tong University School of Medicine Shanghai China

More Ruijin Hospital trials in China

68Ga-grazytracer PET/CT for Early Assessment of Response to Neoadjuvant Immunotherapy in Resectable NSCLC Recruiting
Bronchoscopic Navigation Robot-guided Dye Marking-assisted Thoracoscopic Pulmonary Nodule Resection Recruiting
A Single Cycle of Intravenous Immunoglobulin as Adjuvant to Rituximab in Patients With Pemphigus: A Retrospective Cohort Study at a Tertiary Referral Center Active, not recruiting
Evaluating Omitting of Internal Mammary Irradiation Among Early Stage Intermediate Risk (N1) Breast Cancer Recruiting
Abnormal Glucose Tolerance in Allogeneic Hematopoietic Stem Cell Transplantation Starting soon

Other trials for the same condition

Acostream Use in Patients With High Risk and Intermediate-risk Acute Pulmonary Embolism Recruiting
Effectiveness and Cost-effectiveness of VTE Prevention Strategies in Gynecological Surgery Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06596941 on ClinicalTrials.gov ↗ ← All trials in China